Background {#s0005}
==========

Sex cord-stromal tumours of the gonads are numerous including thecomas, fibromas, Sertoli, Leydig, Sertoli-Leydig cell, and granulosa cell tumours (GCTs) [@b0005]. GCTs are divided into two different types: juvenile and adult [@b0010]. The juvenile type commonly occurs in the first 6 months of life [@b0015]. The adult type is very rare and can occur at any time after puberty. Only 46 cases of adult-type GCT of the testis (AGCTT) have been reported to date [@b0005], [@b0010], [@b0015], [@b0020], [@b0025], [@b0030], [@b0035], [@b0040], [@b0045], [@b0050], [@b0055], [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0145], [@b0150], [@b0155], [@b0160], [@b0165], [@b0170], [@b0175], [@b0180]. Many morphological, clinical, and immunohistochemical characteristics have been identified that help in the diagnosis of AGCTT.

AGCTT presents clinically as a slow, painless enlargement over a variable period of time in \>50% of cases [@b0020], [@b0025], [@b0030]. The mean (range) age at diagnosis is 47 (12--77) years [@b0020], [@b0035]. Erectile dysfunction, gynaecomastia, and decreased libido may also be present [@b0025], [@b0035]. AGCTTs typically have a solid, well-circumscribed, lobular mass that may have a fibrous pseudocapsule in gross morphological analysis.

Some AGCTTs have the potential for distant metastases and thus poor outcomes, but otherwise they are non-functioning, slow growing, and most often benign [@b0020], [@b0040]. A relatively long survival period was found in patients with metastases to regional lymph nodes; however, deaths occurring at few months to a few years after metastases have occurred in patients that have distant metastasis and who exhibited rapid disease progression [@b0040]. The retroperitoneal lymph nodes are the most common metastatic region, but lung, liver, and bone metastases have also been reported [@b0040], [@b0045], [@b0050]. Recent evidence indicates that ≈20% of cases of AGCTT are malignant; however, factors predictive of malignancy have yet to be well defined due to the very limited number of cases.

Case report {#s0010}
===========

A 48-year-old man presented with the complaint of mild pain in his left testis. He denied dysuria, urethral discharge, back pain, abdominal pain, or recent illness. There was no personal or family history of genitourinary disease and his past medical history was not significant. There had been no previous abdominal or genitourinary surgeries and he was a non-smoker. His vital signs were within normal limits and a physical examination was remarkable for tenderness and swelling in the left testis, with a small hard mass at the lower pole on palpation of the left testicle, and the right testicle was unremarkable. Other pertinent findings included the absence of cervical, supraclavicular, or inguinal lymphadenopathy, gynaecomastia, urethral discharge, or scrotal swelling. Abdominal examination revealed no masses or tenderness.

Urine analysis showed no red blood corpuscles, leucocytes, or protein, and was negative for nitrite and leucocyte esterase. Serum tumour markers included lactate dehydrogenase measuring 197 IU/L, serum α~1~-fetoprotein measuring 2 ng/mL, and plasma β human chorionic gonadotrophin measuring \<0.50 IU/mL. Testicular ultrasonography (US) revealed a left testis measuring 3.9 × 1.4 cm with a cystic lesion of 1.2 × 1.2 × 1.0 cm towards its lower pole, with coarse internal echoes, and the wall showed mild irregularity ([Fig. 1](#f0005){ref-type="fig"}).

Contrast-enhanced MRI of the pelvis revealed a well-defined left intra-testicular focal lesion (1.2 × 1.2 × 1.0 cm) at the inferio-posterior aspect of the testis, which had a low signal on T2 weighted imaging (T2WI), and low to iso-intense on T1WI. There was a central high signal on T2WI, suggestive of fluid (necrosis). The tunica albuginea was infiltrated in a small area in the posterior aspect of the lesion to the near-by epididymis ([Fig. 2](#f0010){ref-type="fig"}).

The patient agreed to an orchidectomy after his initial diagnosis and a radical orchidectomy was performed with no complications.

Gross appearance of the specimen revealed a testis with a lower pole well-circumscribed solid mass measuring 1.2 × 1.2 × 1.0 cm. The mass had a fleshy and homogenous cut surface ([Fig. 3](#f0015){ref-type="fig"}). Microscopic evaluation revealed an encapsulated well-circumscribed nodule consisting of micro follicles, cords and solid sheets of tumour cells. The cells appeared elongated with scanty cytoplasm and pale ovoid nuclei. The nuclei had longitudinal grooves giving them a coffee bean-like appearance ([Fig. 4](#f0020){ref-type="fig"}). Very few mitotic figures could be seen. There was no evidence of haemorrhage, necrosis, sarcomatous differentiation or other germ cell elements.

Immunohistochemistry was applied, the tumour cells were strongly positive for vimentin, inhibin ([Fig. 5](#f0025){ref-type="fig"}), calretenin, and cluster of differentiation 99 (CD99). Focal staining for smooth muscle actin, desmin, and cytokeratin (AE1/AE3) was seen. The tumour cells were negative for placental alkaline phosphatase, stem cell marker Oct-3/4, Sal-like protein 4, synaptophysin, chromogranin, and CD117.

Given the histopathological findings, as well as the immunohistochemistry, the patient was diagnosed with AGCTT. The 1-year postoperative surveillance, including CT with oral i.v. contrast and clinical examinations, has been unremarkable.

Discussion {#s0015}
==========

The adult-type GCT is extremely rare in the testis, Schubert et al. [@b0175] have found 43 cases in the literature [@b0005], [@b0010], [@b0015], [@b0020], [@b0025], [@b0030], [@b0035], [@b0040], [@b0045], [@b0050], [@b0055], [@b0060], [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0145], [@b0150], [@b0155], [@b0160], [@b0165], [@b0170], [@b0175], [@b0180] and we were able to find three more recent cases in PubMed ([Table 1](#t0005){ref-type="table"}) [@b0010], [@b0180]. However, in most of the reports these tumours are only the object of immunohistochemical or cytogenetic investigations; thus, the clinical data are missing partially [@b0025], [@b0055], [@b0110], [@b0120]. The initial treatment for all reported cases was radical or inguinal orchidectomy [@b0055], [@b0040]. There is no evidence to support additional therapy in patients with a disease clinically confined to the testicle. Dissection of the retroperitoneal lymph nodes should be considered with pathology suggestive of malignant features or if small-volume metastatic disease is present. If performed, it should be immediately after the orchidectomy. A very poor prognosis is expected for patients with unresectable metastatic, widespread disease [@b0030]. There is no consensus about the treatment for metastatic disease, which may include chemotherapy [@b0055], [@b0040] and/or radiation therapy [@b0060]. In the reported cases of AGCTT, three were treated with chemotherapy. One received cisplatin and doxorubicin 121 months after initial diagnosis and died from disease 13 months later. The next was treated with retroperitoneal lymph node dissection followed by one cycle of etoposide, had a recurrence treated with radical inguinal lymphadenectomy and radiation therapy; and was alive 2 months after the last therapy. The last patient received six cycles of BEP (bleomycin, etoposide, cisplatin) followed by metastasectomy of the right lung and was alive at 39 months after initial diagnosis. Interestingly, Harrison et al. [@b0065] reported an advanced AGCTT partially responding to an angiogenesis inhibitor after initially resisting cytotoxic chemotherapy. Their patient enrolled in a phase I study of pazopanib (GW-786034, GlaxoSmithKline), an oral multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor receptor-1, -2, and -3; platelet-derived growth factor receptor-β; and c-kit. He was treated at the recommended phase II dose (800 mg by mouth daily) and tolerated this therapy well, and ≈32 months after his initial diagnosis the patient died from his disease.

Jimenez-Quintero et al. [@b0055] suggested that haemorrhage, a necrosis size of \>7.0 cm, and presence of lymphovascular invasion, might be indicative of malignancy because these characteristics were present in the malignant cases they identified. In a recent attempt to find variables for malignancy prediction, Hanson and Ambaye [@b0025] evaluated laterality, patient age, presence of gynaecomastia, presence of mitoses, necrosis, and tumour size. Of the variables analysed, only a tumour size of \>5.0 cm showed statistical significance.

US of the abdomen and testis, coupled with clinical examination, may be sufficient in cases thought to have low malignant potential [@b0055]. More extensive follow-up may be warranted with larger tumours or tumours deemed to be aggressive. A follow-up protocol suggested is an abdominal and testicular US along with chest X-ray, with a CT of the abdomen and pelvis every 6 months. The duration of follow-up is not well-defined; however, long-term follow-up is mandatory because metastasis has been found after 10 years of treatment [@b0030].

Conclusion {#s0020}
==========

Further reporting every case of AGCTT, to allow thorough analysis, is necessary to identify factors that can reliably predict tumour behaviour and to optimise methods of diagnosis and treatment together with classic means of follow-up.

Long-term follow-up with a sufficient number of cases may be needed to define optimal treatment options for patients with this rare tumour.

Consent {#s0025}
=======

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Conflicts of interests {#s0030}
======================

The authors declare that they have no competing interests.

Source of Funding {#s0035}
=================

None.

Peer review under responsibility of Arab Association of Urology.

![Left testicular US image with colour flow.](gr1){#f0005}

![MRI showing: A, T1 pre-contrast showing left testicular lesion; B, T1 post-contrast showing left testicular lesion; C, T1 coronal section post-contrast showing left testicular lesion; D, axial section T2 fat suppression; E, T2 coronal section; F, coronal section by multi-planar reconstruction showing no lymph nodes enlarged in the retroperitoneal space.](gr2){#f0010}

![A testicular lower pole well-circumscribed solid mass measuring 1.2 × 1.2 × 1.0 cm. It is fleshy and has a homogenous cut surface.](gr3){#f0015}

![A microscopic section shows elongated tumour cells with scanty cytoplasm and pale ovoid nuclei. The nuclei show longitudinal grooves giving them a coffee bean-like appearance.](gr4){#f0020}

![The tumour cells are strongly positive for inhibin.](gr5){#f0025}

###### 

The morphological and clinical data of the cases reported to date of AGCTT. Modified from Schubert et al. [@b0175].

  Case   Age, years   Testis   Signs and duration, years   Endocrine symptoms   Size, cm      Follow-up, years   Source
  ------ ------------ -------- --------------------------- -------------------- ------------- ------------------ -----------------------------------------
  1      35           Right    15                          Gynaecomastia        9             8.5 NED            Laskowski [@b0070]
  2      21           Left     Incidental                  Gynaecomastia        Microscopic   Autopsy finding    Cohen and Diamond [@b0075]
  3      53           Right    1                           Gynaecomastia        \>10          NS                 Massachusetts General Hospital [@b0080]
  4      52           Right    5                           None                 13            NS                 Melicow [@b0085]
  5      41           Left     8                           Gynaecomastia        10.1          0.42 DOD           Mostofi et al. [@b0090]
  6      53           Right    2                           Gynaecomastia        10            17 NED             Marshall et al. [@b0095]
  7      44           Right    Few months                  None                 3.5           3 NED              Talerman [@b0100]
  8      41           Right    NS                          None                 1.8           NS                 Gaylis et al. [@b0105]
  9      83           Left     NS                          None                 NS            DOC                Düe et al. [@b0110]
  10     61           Right    0.17                        None                 5             2 NED              Nistal et al. [@b0115]
  11     26           Left     0.58                        Gynaecomastia        10            14 NED             Matoska et al. [@b0060]
  12     NS           NS       NS                          NS                   NS            NS                 Sasano et al. [@b0120]
  13     42           Left     NS                          None                 NS            AWD                Monobe and Manabe [@b0125]
  14     57           Right    10                          None                 2.5           3 years DOC        Jimenez-Quintero et al. [@b0055]
  15     55           Left     Not known                   None                 1.3           NS                 Jimenez-Quintero et al. [@b0055]
  16     60           Left     Many years                  None                 7             11.17 DOD          Jimenez-Quintero et al. [@b0055]
  17     39           Left     2                           None                 4             3 NED              Jimenez-Quintero et al. [@b0055]
  18     16           Left     Incidental                  None                 1.8           0.33 NED           Jimenez-Quintero et al. [@b0055]
  19     29           Right    Incidental                  None                 7.5           1.17 AWD           Jimenez-Quintero et al. [@b0055]
  20     76           Left     Incidental                  None                 0.7           0.08 NED           Jimenez-Quintero et al. [@b0055]
  21     NS           NS       NS                          NS                   NS            NS                 Renshaw et al. [@b0130]
  22     NS           NS       NS                          NS                   NS            NS                 Renshaw et al. [@b0130]
  23     NS           NS       NS                          NS                   NS            NS                 Renshaw et al. [@b0130]
  24     NS           NS       NS                          NS                   NS            NS                 Renshaw et al. [@b0130]
  25     NS           NS       NS                          NS                   NS            NS                 Renshaw et al. [@b0130]
  26     NS           NS       NS                          NS                   NS            NS                 Renshaw et al. [@b0130]
  27     51           Left     0.17                        Incidental           7             1.08 NED           Morgan and Brame [@b0135]
  28     48           Right    3                           None                 5             0.58 NED           Al-Bozom et al. [@b0140]
  29     54           Left     Incidental                  None                 NS            NS                 Wang et al. [@b0145]
  30     33           NS       Incidental                  None                 1             NS                 Guzzo et al. [@b0150]
  31     51           Left     Incidental                  None                 NS            6 AWD              Suppiah et al. [@b0045]
  32     59           Left     2                           None                 15            4 NED              Hisano et al. [@b0155]
  33     32           Left     Incidental                  None                 1.98          NS                 Arzola et al. [@b0160]
  34     77           Left     Incidental                  None                 4             NS                 López [@b0165]
  35     45           Right    Months                      None                 6.5           2 NED              Ditonno et al. [@b0030]
  36     12           Left     5                           None                 10            NS                 Gupta et al. [@b0020]
  37     55           NS       Lung metastases             None                 NS            NS                 Hammerich et al. [@b0040]
  38     28           Left     Incidental                  None                 2.6           NS                 Song et al. [@b0170]
  39     21           Left     Incidental                  None                 1             2 NED              Hanson and Ambaye [@b0025]
  40     77           Right    NS                          NS                   2.5           NS                 Lima et al. [@b0005]
  41     22           Left     NS                          NS                   1             NS                 Lima et al. [@b0005]
  42     40           Left     NS                          NS                   2.1           NS                 Lima et al. [@b0005]
  43     78           Left     Incidental                  None                 13            1.92 NED           Schubert et al. [@b0175]
  44     37           Left     Incidental                  None                 4.2           2 NED              Miliaras et al. [@b0010]
  45     22           Left     0.75                        None                 4.6           NS                 Tanner et al. [@b0180]
  46     48           Left     0.25                        None                 2             1 NED              Present case

NS, not specified; NED, no evidence of disease; DOD, dead of disease; AWD, alive with disease; DOC, death from other cause.
